O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.

@article{Kulke2009O6methylguanineDM,
  title={O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.},
  author={Matthew H. Kulke and Jason L Hornick and Christine S Frauenhoffer and Susanne M Hooshmand and David P. Ryan and Peter C. Enzinger and Jeffrey A. Meyerhardt and Jeffrey T. Clark and Keith E. Stuart and Charles S. Fuchs and Mark S. Redston},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2009},
  volume={15 1},
  pages={338-45}
}
PURPOSE Recent studies suggest that temozolomide has activity in neuroendocrine tumors. Low levels of the DNA repair enzyme, O(6)-methylguanine DNA methyltransferase (MGMT), are associated with sensitivity to temozolomide in other tumor types. We evaluated the prevalence of MGMT deficiency in neuroendocrine tumors and correlated MGMT deficiency with treatment response to temozolomide-based regimens. EXPERIMENTAL DESIGN The prevalence of MGMT deficiency, measured by immunohistochemistry, was… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 124 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 47 references

First-line Research. on April 20, 2017

  • J Strosberg, J Choi, N Gardner
  • Clin Cancer Res 2009;15(1)
  • 2009

A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors

  • KulkeMH, K Stuart, C Earle
  • Proc ASCO 2006;12:A4044
  • 2006
1 Excerpt

Similar Papers

Loading similar papers…